小剂量多西环素治疗慢性牙周炎的疗效和对基质金属蛋白酶8的影响

Objective To investigate the effect of low-dose doxycycline(LDD)on the level of gingival crev icular fluid(GCF) matrix metalloproteinases-8 ( MMP-8 ) in chronic periodontitis. Methods Twenty patients with chronic periodontitis were selected and randomly divided into two groups( n = 10 in each group). After scaling and root planning( SRP), the SRP + LDD group received LDD for 3 months, whereas the SRP + P group received placebo 3 months. The patients were evaluated every 3 months during the 12-month study period. The plaque index( PLI), gingival index( GI), probing depth( PD), attachment loss(AL) and GCF samples were collected at each visit. The level of MMP-8 were detected and analyzed. Results Compared to baseline, the scores of PLI, GI, PD, AL and MM P-8 of the two groups showed statistically improvement during the 12-month study period (P ＜ 0.05 ). Compared to the SRP + P group, the SRP + LDD group showed statistically differences of GI, PD at 9,12-month visit. Conclu sion Adjunctive SDD therapy can improve the clinical parameters and this clinical improvement is reflected by level of MMP-8 in chronic periodontitis after the therapy.     

小剂量多西环素治疗慢性牙周炎的疗效和对基质金属蛋白酶8的影响

Objective To investigate the effect of low-dose doxycycline(LDD)on the level of gingival crev icular fluid(GCF) matrix metalloproteinases-8 ( MMP-8 ) in chronic periodontitis. Methods Twenty patients with chronic periodontitis were selected and randomly divided into two groups( n = 10 in each group). After scaling and root planning( SRP), the SRP + LDD group received LDD for 3 months, whereas the SRP + P group received placebo 3 months. The patients were evaluated every 3 months during the 12-month study period. The plaque index( PLI), gingival index( GI), probing depth( PD), attachment loss(AL) and GCF samples were collected at each visit. The level of MMP-8 were detected and analyzed. Results Compared to baseline, the scores of PLI, GI, PD, AL and MM P-8 of the two groups showed statistically improvement during the 12-month study period (P ＜ 0.05 ). Compared to the SRP + P group, the SRP + LDD group showed statistically differences of GI, PD at 9,12-month visit. Conclu sion Adjunctive SDD therapy can improve the clinical parameters and this clinical improvement is reflected by level of MMP-8 in chronic periodontitis after the therapy.     

慢性阻塞性肺疾病和慢性中重度牙周炎患者血清白细胞介素19的表达分析

Objective Periodontitis is an inflammatory disease which may be associated with chronic obstructive pulmonary disease (COPD). Interleukin-19 (IL-19) might be involved in the common inflammatory mechanisms. This study investigated the association of serum levels of IL-19 with periodontitis and COPD in a Chinese population. Methods Fifty-one patients with chronic obstructive pulmonary disease, sixty-one patients with periodontitis, ninety-seven patients with both COPD and periodontitis and twenty-two healthy people were included in the study. The blood serum IL-19 levels was detected by ABC-ELISA. Results The differences in IL-19 expression were significant both between periodontitis group and non-periodontitis group, COPD group and non-COPD group (P ＜ 0.05). However, there was no interaction detected between the two diseases on IL-19 expression. Conclusion Serum IL-19 level increases in both periodontitis patients and COPD patientsand IL-19 might be associated with the pathogenesis of periodontitis and COPD.     

银杏叶提取物对糖尿病大鼠肾脏基质金属蛋白酶2表达的影响

目的 观察银杏叶提取物(GbE)对雄性SD糖尿病大鼠肾脏基质金属蛋白酶2(MMP-2)和Ⅳ型胶原表达的影响,从而探讨银杏叶对糖尿病肾病的保护机制.方法 24只链脲佐菌素诱导的SD大鼠完全随机分成糖尿病对照组(DM组)和GbE组,并以12只正常雄性SD大鼠作为正常对照组(NC组).分别于4、8周后,观察各组大鼠体重、肾重、随机血糖、尿蛋白排泄率等生化指标,并用免疫组化和逆转录聚合酶链反应方法 观察糖尿病大鼠肾脏MMP-2及Ⅳ型胶原的表达.结果 糖尿病大鼠的随机血糖、体重、肾脏/体重明显下降,尿白蛋白排泄率明显升高[DM组(31.59±4.59)mg/24 h比NC组(8.74±2.08)mg/24 h,P＜0.05],GbE组糖尿病大鼠尿白蛋白排泄率[(21.38±3.86)mg/24 h]较DM组有所下降(P＜0.05).8周时,与正常对照组相比,DM组大鼠肾小球MMP-2蛋白的表达水平明显下降[(0.49±0.07)mg/24 h比(0.15±0.04)mg/24 h,P＜0.05],而GbE组DM组大鼠肾小球MMP-2蛋白的表达水平[(0.48±0.07)mg/24 h]较DM组无明显下降(P＞0.05);DM组大鼠Ⅳ型胶原的表达水平较NC组明显升高[(3.48±0.54)mg/24h比(1.68±0.51)mg/24 h],而GbE组糖尿病大鼠较NC组无明显升高[(2.55±0.50)mg/24 h比(1.68±0.51)mg/24 h].结论 GbE可通过抑制糖尿病大鼠MMP-2过表达,进而对糖尿病肾病发挥保护作用.

Abstract：

Objective To study the effect of ginkgo biloba extract (GbE) on the expression of matrix metalloproteinase (MMP)-2 in kidneys of diabetic rates and to analyze the protecting mechanism of GbE on diabetic nephropathy. Methods Totally 24 SD rats of diabetic nephropathy induced by streptozotocin were randomly divided into two groups: diabetes group and treatment group with GbE, and 12 rats with placebo therapy were enrolled as the normal control group. Rats were killed after 4 ～ 8 weeks treatment and the expression of MMP-2 and type Ⅳ collagen were studies by immunohistochemistry and RT-PCR. Results In diabetic rats, blood sugar, weight and kidney/body weight ratio were decreased significantly and the excretion of 24 hour urinary protein was increased significantly compared to the diabetes group. But the excretion of 24 hour urinary protein was improved in GbE group ( P ＜0.05 ). The expression level of MMP-2 protein and mRNA was decreased significantly in renal glomduri of diabetic rats ( P ＜ 0.05 ) but showed no changes in GbE treatment group compared to diabetes group( P ＞ 0.05 ). The expression level of type Ⅳ collagen was significantly increased in diabetic rats( P ＜0.05 ) but showed no changes in GbE group( P ＞0.05). Conclusion GbE can improve diabetic nephropathy by inhibiting the expression of MMP-2 in diabetic Rat.     

银杏叶提取物对糖尿病大鼠肾脏基质金属蛋白酶2表达的影响

Objective To study the effect of ginkgo biloba extract (GbE) on the expression of matrix metalloproteinase (MMP)-2 in kidneys of diabetic rates and to analyze the protecting mechanism of GbE on diabetic nephropathy. Methods Totally 24 SD rats of diabetic nephropathy induced by streptozotocin were randomly divided into two groups: diabetes group and treatment group with GbE, and 12 rats with placebo therapy were enrolled as the normal control group. Rats were killed after 4 ～ 8 weeks treatment and the expression of MMP-2 and type Ⅳ collagen were studies by immunohistochemistry and RT-PCR. Results In diabetic rats, blood sugar, weight and kidney/body weight ratio were decreased significantly and the excretion of 24 hour urinary protein was increased significantly compared to the diabetes group. But the excretion of 24 hour urinary protein was improved in GbE group ( P ＜0.05 ). The expression level of MMP-2 protein and mRNA was decreased significantly in renal glomduri of diabetic rats ( P ＜ 0.05 ) but showed no changes in GbE treatment group compared to diabetes group( P ＞ 0.05 ). The expression level of type Ⅳ collagen was significantly increased in diabetic rats( P ＜0.05 ) but showed no changes in GbE group( P ＞0.05). Conclusion GbE can improve diabetic nephropathy by inhibiting the expression of MMP-2 in diabetic Rat.     

银杏叶提取物对糖尿病大鼠肾脏基质金属蛋白酶2表达的影响

Objective To study the effect of ginkgo biloba extract (GbE) on the expression of matrix metalloproteinase (MMP)-2 in kidneys of diabetic rates and to analyze the protecting mechanism of GbE on diabetic nephropathy. Methods Totally 24 SD rats of diabetic nephropathy induced by streptozotocin were randomly divided into two groups: diabetes group and treatment group with GbE, and 12 rats with placebo therapy were enrolled as the normal control group. Rats were killed after 4 ～ 8 weeks treatment and the expression of MMP-2 and type Ⅳ collagen were studies by immunohistochemistry and RT-PCR. Results In diabetic rats, blood sugar, weight and kidney/body weight ratio were decreased significantly and the excretion of 24 hour urinary protein was increased significantly compared to the diabetes group. But the excretion of 24 hour urinary protein was improved in GbE group ( P ＜0.05 ). The expression level of MMP-2 protein and mRNA was decreased significantly in renal glomduri of diabetic rats ( P ＜ 0.05 ) but showed no changes in GbE treatment group compared to diabetes group( P ＞ 0.05 ). The expression level of type Ⅳ collagen was significantly increased in diabetic rats( P ＜0.05 ) but showed no changes in GbE group( P ＞0.05). Conclusion GbE can improve diabetic nephropathy by inhibiting the expression of MMP-2 in diabetic Rat.     

Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin Ⅱ-stimulated macrophages

AIM: To explore whether the angiotensin Ⅱ (Ang Ⅱ) receptor 1 (AT1) antagonist, losartan could reduce activity and expression of matrix metalloproteinases (MMPs) in rat atherosclerotic plaques. METHODS: Male Wistar-Kyoto rats were ip injected a single dose of vitamin D3 600 kU·kg-1·month-1 and fed an atherogenic diet for 4 months to induce experimental atheroma. Then either placebo or losartan 50 mg·kg-1·d-1 was administered in rats for another 2 months. In vitro, the effect of losartan 0.1-10μmol/L on the expression of MMP-2 and MMP-9 was investigated in Ang II-stimulated rat peritoneal macrophages. The expression and activity of MMP-2 and MMP-9 were monitored by Western blot, RT-PCR, and SDS-PAGE zymography analysis. RESULTS: High levels of MMP-2 and MMP-9 were expressed in rat atherosclerotic lesions. Losartan significantly reduced the activity and expression of MMP-2 and MMP-9 compared with the placebo group (MMP-2, 5861±539 vs 8991±965, P<0.05; MMP-9, 10527±1002 vs 14623±2462, P<0.01). In     

瑞舒伐他汀短期干预对急性冠状动脉综合征患者高敏C反应蛋白及血管性血友病因子和内皮依赖性血管功能的影响

目的 研究瑞舒伐他汀短期干预对急性冠状动脉综合征(ACS)患者血清高敏C反应蛋白(hsCRP)和血管性血友病因子(vWF)水平以及内皮依赖性血管舒张功能的影响.方法 将62例ACS患者完全随机分为他汀组和常规组,各31例,常规组施以常规和安慰剂治疗,他汀组在常规治疗基础上加服瑞舒伐他汀20 mg/d,疗程8周,并于治疗前后分别测定血清hs-CRP、vWF和内皮依赖性血管舒张功能的变化.结果 治疗8周后,常规组的hs-CRP、TC、TG、HDL-C、LDL-C、vWF水平分别为(12.41±5.36)mg/L、(6.31±0.80)mmol/L、(2.65±0.57)mmol/L、(1.33±0.28)mmol/L、(4.20±0.98)mmol/L、(150.68±27.85)%.他汀组上述指标分别为(6.15±2.07)mg/L、(5.87±0.63)mmol/L、(2.38±0.48)mmol/L、(1.48±0.27)mmol/L、(2.91±0.92)mmol/L、(127.46±18.25)%.他汀组治疗后hs-CRP、TG、HDL-C、LDL-C、vWF与治疗前比较,差异有统计学意义(P＜0.01).他汀组治疗后TC、HDL-C与常规组治疗后比较,差异有统计学意义(P＜0.05);他汀组治疗后hs-CRP、LDL-C、vWF与常规组治疗后比较,差异有统计学意义(P＜0.01).结论 应用瑞舒伐他汀对ACS进行干预,在有效调脂的同时可显著降低hs-CRP和vWF水平,改善血管内皮功能,有利于动脉粥样硬化斑块的稳定.

Abstract：

Objective To study the effects of short-term rosuvastatin therapy on high sensitive C-reactive protein (hs-CRP), von Willebrand factor(vWF) and endothelium dependent vasodilatation function in patients with acute coronary syndrome(ACS). Methods Totally 62 patients with ACS were randomly divided into the statin group (n =31 ) and control group (n =31 ). The patients in statin group were treated with Rosuvastain 20 mg/day besides conventional therapy; the patients in control group were treated only with conventional therapy and placebo.The course of therapy was 8 weeks. Plasma levels of hs-CRP and vWF, endothelium dependent vasodilatation function were measured before and after treatment. Results The plasma levels of hs-CRP and vWF in statin group were decreased significantly (P ＜0.01 ), also endothelium dependent vasodilatation function were improved than the patients in control group after 8 weeks. Conclusion It is suggested that short-term therapy with rosuvastatin in patients with ACS could reduces the levels of hs-CRP and vWF and improve the function of endothelium dependent vasodilatation, thus it promotes the stabilization of atheroselerotic plaque.     

结核性胸膜炎不同化疗方案疗效比较

目的 比较不同化疗方案治疗结核性胸膜炎的效果.方法 135例结核性胸膜炎患者完全随机分为2组.治疗组68例,男45例,女23例,平均年龄(41±18)岁,胸膜腔积液(1410±1385)ml,行2HRZE/4HR方案治疗.对照组67例,男46例,女21例,平均年龄(42±16)岁,胸膜腔积液(1263±1156)ml,行4HRZE/2HR方案治疗.2组均行胸膜腔穿刺抽液,胸膜腔中等量和大量积液者使用中心静脉导管胸膜腔内置管引流,并加用泼尼松治疗4～8周.结果 治疗组治愈38例,治愈率55.9%;对照组治愈52例,治愈率77.6%,2组差异有统计学意义(P＜0.01).治疗组与对照组疗程均延长到12个月,治疗组累计治愈率75.1%(51例),对照组累计治愈率95.5%(64例)(P＜0.01).结论 2HRZE不能治愈近半数结核性胸膜炎,临床应根据患者病情制订化疗方案,在完成2个月强化期化疗后依据患者病情决定是否延长强化疗程.完成6个月治疗后,具体考虑是否延长到12个月疗程.

Abstract：

Objective To observe different chemotherapies in the treatment of tuberculous pleurisy results.Methods Totally 135 patients with tuberculous pleurisy were divided into two groups: treatment group (68 cases)and control group( 67 cases). Both groups underwent pleural puncture fluid, pleural effusion, prednisone and central venous catheter drainage plus pleural catheter drainage. The therapy lasted from 4 to 8 weeks. Results In the treatment group,38cases were cured and the cure rate was 55.9%. In the control group,52 cases were cured and the cure rate was 77.6%. At 12 months, the total cure rate of treatment rate was 75.1% (51) and the total cure rate of control rate was 95.5% (64) ( P ＜ 0.01 ). Conclusion The short-course chemotherapy of two months cannot cure nearly half of tubercular pleurisy patients. The chemotherapy plan should be decided according to patient' s condition after a two-month reinforcement chemotherapy period. By the end of six-month course, An extension of 12- month course should be considered at the end of the 6 months' therapy.     

复方多西环素缓释凝胶对实验性牙周炎龈沟液IL-4和 TNF-α的影响

目的：研究复方多西环素缓释凝胶对实验性牙周炎大鼠牙龈指数（ GI）、牙周袋深度（ PD）、附着丧失程度（AL）及龈沟液中白介素-4（IL-4）和肿瘤坏死因子-α（TNF-α）水平的影响。方法选用Wister大鼠42只,随机分为3组：正常对照组（N组）,阳性对照组（C组）和实验组（T组）,每组14只。 C组和T组建立牙周炎模型后,C组给米诺环素软膏治疗,T组给复方多西环素缓释凝胶治疗,均为每周上药1次共4次,并分别在治疗前和治疗后记录GI、PD、AL及龈沟液中IL-4和TNF-α水平。结果治疗后,C组和T组GI、PD、AL均较治疗前显著下降（ P ＜08．05）。牙周炎大鼠龈沟液中IL-4水平显著低于正常组（ P ＜0．05）,治疗后显著增高（ P ＜0．05）,且T组明显高于C组（ P ＜0．05）;牙周炎大鼠龈沟液中TNF-α水平显著高于正常组（ P ＜0．05）,治疗后显著降低（ P ＜0．05）,T组和C组治疗后差异无统计学意义（ P ＞0．05）。结论复方多西环素缓释凝胶能明显改善牙周炎临床症状,显著降低龈沟液中TNF-α水平,提高龈沟液中IL-4水平。     

排龈术对楔状缺损修复后龈沟液MMP-8水平的影响

目的通过测定龈沟液(GCF)内基质金属蛋白酶-8(MMP-8)的水平,评估排龈术对楔状缺损修复后牙周状况的影响。方法选择患楔状缺损的下颌前磨牙84颗,分为A、B两组,每组42颗受试牙,A组排龈后用3MZ350纳米树脂充填,B组直接用3MZ350纳米树脂充填,分别在术前、术后1、3、6个月时进行临床指标(PLI、GI、GCD)检查和龈沟液取样,对GCF量和MMP-8水平进行测定。结果术前、术后1个月时,A、B两组各项指标均无统计学差异(P>0.05);术后3、6个月时,A、B两组各临床指标无统计学差异(P>0.05),而GCF量和MMP-8水平差异有统计学意义(P<0.05)。结论排龈术用于楔状缺损修复能减少对患牙牙周组织的损伤。     

大黄素温敏凝胶对慢性牙周炎患者龈沟液Ⅱ型胶原酶活性的影响

目的 探讨牙周炎患者局部应用大黄素温敏凝胶对其龈沟液中Ⅱ型胶原酶(COL-Ⅱ)活性的影响及其临床疗效.方法 选取40例慢性牙周炎患者,采用同一口腔内病情相同牙齿的自身对照研究设计,分为观察组40个牙和对照组40个牙,在基线前须完成全口龈上洁治及口腔卫生宣教,基线时试验牙取龈沟液样本(测定胶原酶),记录菌斑指数、探诊深度、附着丧失和齿沟出血指数及牙齿松动度,然后行龈下刮治术,用药侧每周放1次药,共4次,对照侧按常规治疗.分别于治疗前及治疗后4周收集患牙的龈沟液并记录相关临床指标.采用双抗体夹心酶联免疫法检测龈沟液中COL-Ⅱ活性.结果 两组治疗前COLⅡ水平及牙菌斑指数、齿沟出血指数、牙周袋深度、牙周附着水平、牙齿松动度等差异均无统计学意义(均P＞0.05);治疗1个疗程后,观察组龈沟液中COL-Ⅱ水平及牙菌斑指数、齿沟出血指数、牙周袋深度、牙周附着水平、牙齿松动度与对照组差异均有统计学意义(t =3.46、4.02、4.18、3.03、2.79、4.29,均P＜0.05).结论 应用大黄素温敏凝胶作为牙周炎基础治疗的辅助疗法,能有效降低龈沟液中Ⅱ型胶原酶活性,从而有效阻止牙周组织的破坏.     

米诺环素辅助治疗重度牙周炎的临床研究

目的评价派里奥软膏局部应用辅助治疗重度牙周炎的疗效。方法32例重度牙周炎患者，共192颗患牙，全口洁治和根面平整后，以患者一侧患牙局部应用派里奥软膏为实验组，对侧同名患牙局部应用牙康（甲硝唑棒）为对照组，记录基线、用药后第4周、8周菌斑指数（PLI）、龈沟出血指数（SBI）、牙周探诊深度（PD）、牙周附着水平（AL）．并进行数据分析。结果第4周、8周PLI、SBI、PD、AL较基线时均由改善（P〈0．01）；实验组第8周较第4周除PLI略有反弹外，其余指标皆进一步改善；在两个观察时段实验组较对照组在SBI、PD、AL方面，差异有统计学意义（P〈0．01），但PLI两组间差异无统计学意义（P〉0．05）。结论派里奥软膏局部应用辅助治疗重度牙周炎有较好的临床效果，优于牙康。     

慢性牙周炎患者龈沟液中肿瘤坏死因子水平的检测

目的探讨慢性牙周炎患者龈沟液肿瘤坏死因子(Tumor necrosis factor alpha,TNF-α)水平变化及其与牙周指标相关性。方法用酶联免疫测定患有慢性牙周炎的20个牙位和牙周健康的20个牙位的龈沟液中肿瘤坏死因子水平。并记录相关临床指标。结果慢性牙周炎患牙龈沟液中肿瘤坏死因子水平明显高于健康对照,并且龈沟液中肿瘤坏死因子水平与牙周袋探诊深度(Probing Depth,PD)、附着丧失(Attachment Loss,AL)水平均呈正相关关系。结论龈沟液中肿瘤坏死因子水平与牙周组织的破坏和牙周病的严重程度有关。     

中度儿童龈炎临床指标与龈沟液量的相关性分析

目的：观察中度儿童龈炎的临床指标：菌斑指数（PLI）、出血指数（BI）、牙龈指数（GI）与龈沟液（GcF）的量,探讨GCF量与PLI、BI、GI在儿童龈炎发生发展过程中的变化,分析GCF量与PLI、BI、GI的相关性。方法：选择临床诊断为中度儿童龈炎患者52例156颗牙,在实施治疗措施的第0、3、7、14、21、28天分别对菌斑指数（PLI）、出血指数（BI）、牙龈指数（GI）与龈沟液（GCF）量进行检测与相关性分析。结果：中度牙龈炎儿童治疗后第7、14、21、28天PLI、BI、GI的数值与第一时间点比较,差异均具有统计学意义（P〈0．01）;龈沟液的量治疗后第21天与第一时间点比较,差异有统计学意义,P〈0．05;第28天与第一时间点比较,差异具有统计学意义,P〈0．01;各检查时间GCF量与PLI、BI、GI均呈正相关关系。结论：在儿童龈炎发生过程中,中度牙龈炎的GCF量与PLI、BI、GI间的均呈正相关关系;GCF量与龈炎发生程度密切相关,可作为评价牙龈炎趋向性的动态指标。     

复方茶多酚膜剂治疗糖尿病患者牙周炎的临床观察

目的:观察复方茶多酚膜剂对2型糖尿病患者牙周炎的临床疗效。方法:将72例2型糖尿病并发慢性牙周炎患者采用区组随机化分组法随机均分为试验组与对照组,对照组采用基础治疗,试验组在对照组基础治疗上加用复方茶多酚膜剂辅助治疗,观察用药前,用药第4、8周时的牙周临床指标(菌斑指数、牙龈指数、探诊深度、附着丧失)。结果:用药后第4、8周2组患者牙周临床指标均有显著改善(P<0.05),且试验组牙周临床指标改善优于对照组(P<0.05)。2组均未见明显不良反应发生。结论:复方茶多酚膜剂可以明显改善糖尿病患者牙周基础治疗后的疗效。     

吸烟合并慢性牙周炎患者龈沟液NO含量检测

目的检测吸烟的慢性牙周炎患者牙周基础治疗前后龈沟液内NO含量,与不吸烟患者的进行比较,结合牙周炎临床症状的改善情况,探讨吸烟与牙周炎的关系。方法在口腔内科门诊选取患有慢性牙周炎患者20例,随机分为吸烟组和不吸烟组。在牙周炎治疗前后分别采集龈沟液标本,免疫荧光法检测龈沟液NO含量进行分析,同时记录牙周炎临床症状的改善程度。结果两组经牙周基础治疗后NO含量均有明显下降,吸烟者的含量显著高于不吸烟者,牙周炎临床指标的变化表明吸烟者治疗前后的变化显著小于不吸烟者。结论吸烟与导致牙周炎相关且影响牙周炎的治疗效果。     

牙周炎患者不同种植系统修复的临床评价

目的:探讨牙周炎患者不同种植系统修复后种植体边缘骨吸收(MBL)及龈沟液(GCF)中主要生物标志物的差异性。方法:选择2017年—2018年就诊的Ⅲ期牙周炎患者36例,共植入种植体91枚,随机分为士卓曼组、奥齿泰组和威高组。士卓曼组植入士卓曼(Straumann)种植体33枚,奥齿泰组植入奥齿泰(OSSTEM)种植体30枚,威高组植入威高(WEGO)种植体28枚。修复完成后6个月、1年和2年复诊,记录口腔各项临床指标及种植体存留率,测量种植体MBL,并检测龈沟液中白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)和基质金属蛋白酶-8(MMP-8)水平。结果:三组成功率均为100%,奥齿泰组、威高组术后1年、2年的MBL值高于士卓曼组(P<0.05),士卓曼组术后龈沟液中IL-1β和TNFα及MMP-8低于奥齿泰组、威高组(P<0.05),其中MMP-8水平差异更显著(P<0.01)。结论:士卓曼组边缘骨吸收及种植体周围龈沟液中生物标志物水平低于其他两组,提示在种植体周围炎发生方面存在更低风险,可能取得更好的长期种植稳定性。     

盐酸米诺环素软膏联合洗必泰碘药膜对牙周炎患者临床疗效、PLI、PD及GI的影响

目的探讨盐酸米诺环素软膏联合洗必泰碘药膜对牙周炎患者临床疗效、PLI、PD及GI的影响。方法选择2018年5月至2020年3月在我院接受治疗的牙周炎患者84例进行研究。随机分为2组,每组各42例。对照组在常规治疗基础上加以洗必泰碘药膜治疗,观察组在对照组基础上加以盐酸米诺环素软膏治疗。比较两组患者临床疗效、PLI、PD、GI、牙龈沟液炎症因子及不良反应。结果观察组总有效率为95.23%,高于对照组的80.96%(P<0.05)。治疗后两组患者PLI、PD、GI、IL-6、IL-8及TNF-α水平均明显下降,但观察组下降幅度更大(P<0.05)。对照组共出现3例(7.14%)不良反应,给药部位不适2例,皮肤瘙痒1例,观察组共出现4例(9.52%)不良反应,给药部位不适2例,皮肤瘙痒1例,恶心1例,不良反应经对症治疗后均得到控制,两组差异无统计学意义(P>0.05)。结论盐酸米诺环素软膏联合洗必泰碘药膜较单独使用洗必泰碘药膜可有效提高牙周炎患者临床疗效,降低、PLI、PD及GI水平,缓解炎症反应且具有较高的安全性。